Get the Stockscreener App
1.67
2.34%
-0.04
After Hours:
1.64
-0.03
-1.80%
Reviva Pharmaceuticals Holdings Inc. stock is currently priced at $1.67, with a 24-hour trading volume of 304.15K.
It has seen a -2.34% decreased in the last 24 hours and a -47.81% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.70 pivot point. If it approaches the $1.63 support level, significant changes may occur.
Previous Close:
$1.71
Open:
$1.71
24h Volume:
304.15K
Market Cap:
$46.62M
Revenue:
-
Net Income/Loss:
$-37.65M
P/E Ratio:
-1.1844
EPS:
-1.41
Net Cash Flow:
$-24.14M
1W Performance:
-10.70%
1M Performance:
-47.81%
6M Performance:
-58.35%
1Y Performance:
-79.07%
1D Range:
$1.62
$1.72
52W Range:
$1.60
$8.30
Reviva Pharmaceuticals Holdings Inc. Stock (RVPH) Company Profile
Name
Reviva Pharmaceuticals Holdings Inc.
Sector
Industry
Phone
408 501 8881
Address
19925 Stevens Creek Boulevard, Suite 100, Cupertino
Reviva Pharmaceuticals Holdings Inc. Stock (RVPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-24-22 | Initiated | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc. Stock (RVPH) Latest News
Reviva Pharmaceuticals Progresses with Global Schizophrenia Trial - TipRanks.com - TipRanks
TipRanks
Reviva Pharmaceuticals Progresses with Global Schizophrenia Trial - TipRanks.com - TipRanks
TipRanks
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - GlobeNewswire
GlobeNewswire
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - WICZ
WICZ
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - Yahoo Finance
Yahoo Finance
Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
The InvestChronicle
Reviva Pharmaceuticals Holdings Inc. Stock (RVPH) Financials Data
Reviva Pharmaceuticals Holdings Inc. (RVPH) Net Income 2024
RVPH net income (TTM) was -$37.65 million for the quarter ending September 30, 2023, a -89.16% decrease year-over-year.
Reviva Pharmaceuticals Holdings Inc. (RVPH) Cash Flow 2024
RVPH recorded a free cash flow (TTM) of -$24.14 million for the quarter ending September 30, 2023, a -32.83% decrease year-over-year.
Reviva Pharmaceuticals Holdings Inc. (RVPH) Earnings per Share 2024
RVPH earnings per share (TTM) was -$1.67 for the quarter ending September 30, 2023, a -53.21% decline year-over-year.
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, as well as for treating pulmonary arterial hypertension and idiopathic pulmonary fibrosis. The company is based in Cupertino, California.
0.77%
1.20%
Cap:
|
Volume (24h):